Abstract: A system for DNA gene assembly that utilizes a DNA symbol library and a DNA linker library. The symbol library has a number of DNA symbols each having a first overhanging end and a second overhanging end different than and non-complimentary to the first end, the first and second ends being the same nucleotides for each DNA symbol. The linker library has pairs of DNA linkers, a first linker of a pair having a first end and a second end and a second linker of the pair having a first end and a second end, the first end of the first linker being the same nucleotides for each first linker and the second end of the second linker being the same nucleotides for each second linker, wherein the second end of the first linker and the first end of the second linker have complementary nucleotides. The first linker joins to the first end of a DNA symbol and the second linker joins to the second end of another DNA symbol.
Type:
Grant
Filed:
June 15, 2021
Date of Patent:
May 9, 2023
Assignee:
SEAGATE TECHNOLOGY LLC
Inventors:
Tim Rausch, Walter R Eppler, Gemma Mendonsa
Abstract: Disclosed are polynucleotides, compositions, and methods related to RNA interference (RNAi). The disclosed polynucleotides, compositions, and methods may be utilized for treating diseases and disorders through RNAi. Particular disclosed are toxic RNAi active seed sequences and methods of using toxic RNAi active sequences for killing cancer cells. The disclosed toxic RNAi active seed sequences preferentially target and inhibit the expression of multiple essential genes for cell survival and/or growth through a process called “death-induced by survival gene elimination” or “DISE.
Type:
Grant
Filed:
February 20, 2018
Date of Patent:
March 28, 2023
Assignee:
Northwestern University
Inventors:
Marcus E. Peter, William E. Putzbach, Andrea E. Murmann, Monal Patel, Quan Gao
Abstract: Provided herein are RNAi molecules for treating Huntington's disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease.
Type:
Grant
Filed:
September 21, 2018
Date of Patent:
March 14, 2023
Assignee:
GENZYME CORPORATION
Inventors:
Catherine R. O'Riordan, Adam Palermo, Brenda Richards, Lisa M. Stanek
Abstract: A ?-modified phosphoric acid compound precursor that inhibits the progress of a phosphorylation reaction having a partial structure represented by where A1 represents —SR1, —S—S—R1, —SeR1, or —X, where X is a halogen selected from fluoro, chloro, bromo, and iodo; R1 represents hydrogen, an alkyl group having 1 to 20 carbon atoms, or the like; L1 represents hydrogen, an alkyl group having 1 to 20 carbon atoms, or the like; L2 represents an alkyl group having 1 to 20 carbon atoms, or the like; L1 and L2 may be linked to each other to form a 4 to 6-membered ring structure; L1 and L2 may each have a substituent; and the symbol * represents a bond to be bonded to a phosphate group by phosphorylation. Further, provided are a reaction inhibitor and a medicine, each of which includes the ?-modified phosphoric acid compound precursor.
Abstract: The present invention relates to new methods for diagnosing a pregnancy-associated disorder by analyzing fetal DNA present in the mother's blood. More specifically, this invention relies on the discovery that the maspin gene is differentially methylated in fetal DNA and in maternal DNA and provides these new diagnostic methods, which distinguish fetal DNA from maternal DNA and detect prenatal disorders based on abnormalities in fetal DNA level and methylation status.
Type:
Grant
Filed:
March 2, 2020
Date of Patent:
March 7, 2023
Assignee:
The Chinese University of Hong Kong
Inventors:
Yuk Ming Dennis Lo, Wai Kwun Rossa Chiu, Stephen Siu Chung Chim, Yu-Kwan Tong, Chunming Ding
Abstract: The present disclosure provides a novel integrated entropy-based method that combines genome-wide profiling and network analyses for diagnostic and prognostic applications. The present disclosure further provides the integration of multiomics datasets, network analyses and machine learning that enable predictions on diagnosing infectious diseases and predicting the probability that they will escape treatment/the host immune system and/or become antibiotic resistant. The present disclosure provides a primary gateway towards the development of highly accurate infectious disease prognostics.
Type:
Grant
Filed:
April 3, 2020
Date of Patent:
February 28, 2023
Assignee:
The Trustees of Boston College
Inventors:
Tim van Opijnen, Zeyu Zhu, Defne Surujon
Abstract: The present disclosure provides materials and methods for the delivery of therapeutic nucleic cells (and imaging agents) to tissues.
Type:
Grant
Filed:
May 8, 2019
Date of Patent:
February 21, 2023
Assignees:
UNIVERSITY OF MIAMI, UNIVERSITY OF MODENA AND REGGIO EMILLA—UNIMORE
Inventors:
Paolo Serafini, Dimitri Van Simaeys, Adriana De La Fuente, Alessia Zoso, Silvio Bicciato, Jimmy Caroli, Cristian Taccioli, Andrea Grilli, Midhat Abdulreda
Abstract: Embodiments of the present invention provide plant-derived extracts as a replacement for traditional cryoprotectants used to freeze tissue and cells providing a method to decrease post-thaw damage as created by the cryoprotectant. For example, extracts from the genus Hippophae or other plant sources or compositions may be used as a cryoprotectant or may even be used to replace at least some of a traditional cryoprotectant.
Abstract: Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand.
Type:
Grant
Filed:
August 2, 2021
Date of Patent:
January 31, 2023
Assignee:
UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Inventors:
Jesse Salk, Lawrence A. Loeb, Michael Schmitt
Abstract: The invention relates to a method for the detection of the occurrence of initiation of replication events in genomic DNA in a eukaryotic cell, involving contacting said eukaryotic cell comprising said genomic DNA with a first nucleotide probe, under conditions enabling in situ hybridization of said first nucleotide probe with a target region in the DNA genome, wherein said target region comprises a nucleic acid sequence which has no identified corresponding annealing RNA in a metabolically active cell and therefore remains RNA-free during transcription and replication of said DNA genome and detecting said first nucleotide probe hybridized to said DNA. Further detection of at least one RNA molecule can be achieved.
Type:
Grant
Filed:
April 27, 2018
Date of Patent:
January 31, 2023
Assignees:
INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Abstract: Mice, embryos, cells, and tissues having a restricted immunoglobulin heavy chain locus and an ectopic sequence encoding one or more ADAM6 proteins are provided. In various embodiments, mice are described that have humanized endogenous immunoglobulin heavy chain loci and are capable of expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof that is functional in a male mouse. Mice, embryos, cells, and tissues having an immunoglobulin heavy chain locus characterized by a single human VH gene segment, a plurality of human DH gene segments and a plurality of human JH gene segments and capable expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof are also provided.
Type:
Grant
Filed:
December 4, 2019
Date of Patent:
January 24, 2023
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Lynn Macdonald, Sean Stevens, Andrew J. Murphy, Margaret Karow, John McWhirter
Abstract: The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide.
Type:
Grant
Filed:
January 25, 2013
Date of Patent:
January 24, 2023
Assignee:
Janssen Pharmaceutica NV
Inventors:
Tatiana I. Vener, Carlo C. Derecho, John F. Palma, Mical Raponi
Abstract: This invention relates to methods and compositions for coupling nucleic acid to a functionalized surface or support. In particular, the present invention provides an improved process for coupling aminated nucleic acid to a support functionalized with carboxylic acid groups, wherein the coupling reaction is conducted in the presence of an organic solvent. The invention further relates to compositions and kits for performing the coupling reaction and uses of nucleic acid-loaded supports for various applications.
Abstract: The present invention relates to methods for treating and/or preventing tumors and/or promoting apoptosis in a neoplastic cell comprising contacting the neoplastic cell with an cell-penetrating dominant-negative ATF5 (“CP-d/n-ATF5”), wherein the CP-d/n-ATF5 is capable of inhibiting ATF5 function and/or activity.
Type:
Grant
Filed:
December 7, 2020
Date of Patent:
January 17, 2023
Assignees:
The Trustees of Columbia University in the City of New York, The Regents of the University of California
Abstract: Phosphatidylinositol 3-kinases (PI3Ks) are known to be important regulators of signaling pathways. To determine whether PI3Ks are genetically altered in cancers, we analyzed the sequences of the PI3K gene family and discovered that one family member, PIK3CA, is frequently mutated in cancers of the colon and other organs. The majority of mutations clustered near two positions within the PI3K helical or kinase domains. PIK3CA represents one of the most highly mutated oncogenes yet identified in human cancers and is useful as a diagnostic and therapeutic target.
Type:
Grant
Filed:
October 7, 2019
Date of Patent:
January 10, 2023
Assignee:
The Johns Hopkins University
Inventors:
Yardena Samuels, Victor E. Velculescu, Kenneth W. Kinzler, Bert Vogelstein
Abstract: The present disclosure provides novel bacterial strains with altered expression or start codon modification of one or more RNA degradation/processing genes. The RNA degradation genes of the present disclosure are controlled by heterologous promoters. The present disclosure further describes methods for generating microbial strains comprising heterologous promoter sequences operably linked to RNA degradation/processing genes.
Abstract: Described herein are methods and compositions for genomic editing. Endonucleases for genomic editing involve inducing breaks in double stranded DNA, for which knock-ins are notoriously inefficient for relying on random integration of homologous DNA sequences into the break site by repair proteins. To address these issues, described herein are novel recombinant fusion proteins that actively recruit linear DNA inserts in closer proximity to the genomic cleavage site, increasing integration efficiency of large DNA fragments into the genome. Such improvements to genomic editing technology allow one to use lower linear DNA concentrations without sacrificing efficiency and can be further combined with other features, such as fluorescent protein reporting systems.
Type:
Grant
Filed:
May 13, 2016
Date of Patent:
December 27, 2022
Assignee:
University of Southern California
Inventors:
Jason Junge, Timothy Hunt, Scott E. Fraser
Abstract: This invention provides a kit or device for detection of prostate cancer and a method for detecting prostate cancer. This invention provides a kit or device for detection of prostate cancer comprising a nucleic acid capable of specifically binding to an miRNA in a sample from a subject or a complementary strand thereof and a method for detecting prostate cancer comprising measuring the miRNA in vitro.
Type:
Grant
Filed:
August 9, 2019
Date of Patent:
December 27, 2022
Assignees:
TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
Abstract: According to an aspect, provided are: a guide RNA; a vector comprising the same; a composition for removing a nucleic acid sequence encoding a KRAS polypeptide in the genome of a cell, containing the same; a composition for preventing or treating cancer, containing the same; and a method using the same. The present invention enables the mutation of a nucleic acid sequence encoding a KRAS polypeptide in the genome of a cell or a subject and, particularly, can be usable, as personalized or precision medical care, in the prevention or treatment of cancer.
Type:
Grant
Filed:
October 16, 2017
Date of Patent:
November 29, 2022
Assignee:
INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
Inventors:
Hyong Bum Kim, Won Joo Kim, Han Sang Kim
Abstract: Compositions, systems, and methods for the display of analytes such as biomolecules are described. Display of analytes is achieved by coupling of the analytes to displaying molecules that are configured to associate with surfaces or interfaces. Arrays of analytes may be formed from the described systems for utilization in assays and other methods.
Type:
Grant
Filed:
March 10, 2022
Date of Patent:
November 22, 2022
Assignee:
Nautilus Biotechnology, Inc.
Inventors:
Tural Aksel, Stephen Hendricks, Elvis Ikwa, Pierre Indermuhle, Sadie Ingle, Christina Inman, Parag Mallick, Torri Elise Rinker, Steven Tan
Abstract: The subject invention relates in part to the surprising discovery that Cry1Da is active against corn earworm (CEW), Helicoverpa zea (Boddie). Methods for using Cry1Da in transgenic plants to prevent serious crop damage is described. Leaf and silk bioassays using transgenic maize expressing full length, core toxin region or chimeric Cry1Da demonstrated good insect protection against CEW larvae damage.
Type:
Grant
Filed:
May 18, 2020
Date of Patent:
November 1, 2022
Inventors:
Sek Yee Tan, Joel J Sheets, Todd P Glancy, Aaron Todd Woosley, Sarah E Worden, Diaa Alabed, Stephanie Love Burton, Karen C McLaughlin, Kenneth Narva, Thomas Meade
Abstract: Improved compositions and methods for treating a disease or disorder through target exon skipping, and preferably muscular dystrophy by administering antisense thiomorpholino molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping to produce a functional Dystrophin protein.
Type:
Grant
Filed:
March 20, 2020
Date of Patent:
October 25, 2022
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO
Inventors:
Marvin Caruthers, Sibasish Paul, Rakesh N. Veedu, Katarzyna Jastrzebska, Heera Krishna
Abstract: This application provides methods, kits, probes and primers, that can be used to analyze environmental samples, such as water samples, soil samples, and air samples. The methods and kits can include positive controls, to provide confidence in test results.
Type:
Grant
Filed:
October 10, 2017
Date of Patent:
October 25, 2022
Assignee:
UVic Industry Partnerships Inc.
Inventors:
Caren Christiane Helbing, Nicholas Veldhoen
Abstract: The present invention relates to novel nucleic acid molecules, called aptamers, that bind specifically to a small molecule fluorophore and thereby enhance the fluorescence signal of the fluorophore upon exposure to radiation of suitable wavelength. Molecular complexes formed between the novel fluorophores, novel nucleic acid molecules, and their target molecules are described, and the use of multivalent aptamer constructs as fluorescent sensors for target molecules of interest are also described.
Abstract: Provided are compositions comprising an oligonucleotide that targets Thymic stromal lymphopoietin (TSLP). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating an airway disorder by providing an oligonucleotide that targets TSLP to a subject in need thereof. In some embodiments, the oligonucleotide targeting is specific for a long isoform of TSLP (1fTSLP).
Type:
Grant
Filed:
January 3, 2020
Date of Patent:
September 27, 2022
Assignee:
EMPIRICO INC.
Inventors:
Omri Gottesman, Shannon Bruse, Brian Cajes, David Lewis, David Rozema
Abstract: The present invention relates to a method for single-cell imaging mass spectrometry (MS) by correlating an optical image of a cell sample with an MS image. The method of the invention is in particular useful in research to test concomitantly optical and molecular phenotypes at a single-cell resolution.
Abstract: Sensing the electric or strain field experienced by a sample containing a crystal host comprising of solid state defects under a zero-bias magnetic field can yield a very sensitive measurement. Sensing is based on the spin states of the solid-state defects. Upon absorption of suitable microwave (and optical) radiation, the solid-state defects emit fluorescence associated with hyperfine transitions. The fluorescence is sensitive to electric and/or strain fields and is used to determine the magnitude and/or direction of the field of interest. The present apparatus is configured to control and modulate the assembly of individual components to maintain a zero-bias magnetic field, generate an Optically Detected Magnetic Resonance (ODMR) spectrum (with or without optical excitation) using appropriate microwave radiation, detect signals based on the hyperfine state transitions that are sensitive to electric/strain fields, and to quantify the magnitude and direction of the field of interest.
Type:
Grant
Filed:
March 16, 2020
Date of Patent:
September 20, 2022
Assignee:
Massachusetts Institute of
Technology
Inventors:
Danielle Ann Braje, Edward H. Chen, Phillip R. Hemmer
Abstract: Provided herein are compositions and systems for use in polymerase-dependent, nucleotide transient-binding methods. The methods are useful for deducing the sequence of a template nucleic acid molecule and single nucleotide polymorphism (SNP) analyses. The methods rely on the fact that the polymerase transient-binding time for a complementary nucleotide is longer compared to that of a non-complementary nucleotide. The labeled nucleotides transiently-binds the polymerase in a template-dependent manner, but does not incorporate. The methods are conducted under any reaction condition that permits transient binding of a complementary or non-complementary nucleotide to a polymerase, and inhibits nucleotide incorporation.
Type:
Grant
Filed:
March 20, 2020
Date of Patent:
September 20, 2022
Assignee:
LIFE TECHNOLOGIES CORPORATION
Inventors:
Peter Vander Horn, Cheng-Yao Chen, Guobin Luo, Michael Previte, Jamshid Temirov, Theo Nikiforov, Zhaohui Zhou, Hongye Sun, Yufang Wang, Stefanie Yukiko Nishimura, Hongyi Wang, Marian Peris, Barnett Rosenblum, Michael Phelan
Abstract: The invention described in the application relates to a panel of gene expression markers for patient with a tumor. The invention thus provides methods and compositions, e.g., kits, for evaluating gene expression levels of the markers and methods of using such gene expression levels to evaluate the likelihood of disease progression or response to chemotherapy or radiation therapy. Such information can be used in determining prognosis and treatment options for cancer patients.
Type:
Grant
Filed:
May 18, 2015
Date of Patent:
September 6, 2022
Assignee:
The Regents of the University of California
Inventors:
Weiguo Zhang, Gary Karpen, Jian-Hua Mao
Abstract: A vaccine composition for immunizing and/or protecting a mammal against an IL-31 mediated disorder is provided, wherein the composition includes: the combination of a carrier polypeptide and at least one mimotope selected from a feline IL-31 mimotope, a canine IL-31 mimotope, a horse IL-31 mimotope, and a human IL-31 mimotope; and an adjuvant. Such vaccines can be in the form of pharmaceutical compositions useful for treating or protecting mammals such as cats, dogs, horses, or humans against IL-31-mediated disorders.
Type:
Grant
Filed:
March 18, 2019
Date of Patent:
September 6, 2022
Assignee:
Zoetis Services LLC
Inventors:
Gary Francis Bammert, Steven Alan Dunham
Abstract: A ribonucleic acid compound is disclosed, the ribonucleic acid compound comprising, or consisting of, an RNA sequence having at least 90% sequence identity to SEQ ID NO: 1, wherein said RNA sequence has a length of 29 nucleotides or fewer, and wherein the RNA sequence is capable of binding to a transferrin receptor (TfR).
Abstract: Disclosed are dendritic anionic lipids which are compounds of Formula (I): wherein R and R1 are non-polar groups, L is a linking moiety, and Dm is a dendritic moiety of m generations, each as defined herein. These dendritic anionic lipids are useful for delivery and expression of m RNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Type:
Grant
Filed:
February 10, 2021
Date of Patent:
August 30, 2022
Assignee:
Translate Bio, Inc.
Inventors:
Michael Heartlein, Frank DeRosa, Shrirang Karve
Abstract: Disclosed herein include systems, methods, compositions, and kits for in situ readout of barcodes, such as DNA barcodes. Barcode constructs containing a promoter (e.g., a phage promoter) that is inactive in live cells can be integrated in the genomes of cells. Cells can be fixed, and phage RNA polymerase can be used for transcription of the barcode to RNA transcripts. The RNA transcripts can be detected using, for example, fluorescent imaging and used to determine barcode sequences.
Type:
Grant
Filed:
December 2, 2019
Date of Patent:
August 23, 2022
Assignee:
California Institute of Technology
Inventors:
Amjad Askary, Michael B. Elowitz, Mark W. Budde, Carlos Lois, Luis Sanchez Guardado, Long Cai, James Linton
Abstract: The present disclosure relates to methods, processes and systems for enzymatic synthesis of oligonucleotide from a single-stranded, immobilized primer in the presence of a polymerase. Using the disclosed methods single-stranded oligonucleotides can be synthesized enzymatically from a single-stranded, immobilized primer in the presence of deoxyribonucleotide triphosphates or ribonucleotide triphosphates. Dideoxyribonucleotide triphosphates, deoxyribonucleotide triphosphates with reversible terminators, or ribonucleotide triphosphates with reversible terminators can be added enzymatically to the end of the primer or its extension products. According to the disclosed method, a single-stranded primer can bind to a template such that the thus-formed double-stranded structure can allow the polymerase to extend the primer at 3? end.
Abstract: The present invention relates to a highly efficient aptamer complex comprising a branched DNA and an aptamer, and a pharmaceutical use thereof. More specifically, the aptamer complex of the present invention relates to a highly efficient aptamer complex including a Y-shaped DNA as the branched DNA and using vascular endothelial growth factor (VEGF) as a target molecule. The aptamer complex of the present invention and a pharmaceutical composition comprising the same as an active ingredient are expected to be widely used in the medical field since the binding efficiency with the target molecule is more remarkable than that of the conventional aptamer.
Abstract: The invention generally relates to compositions for maximizing capture of affinity-labeled molecules on solid supports. The disclosed methods and compositions were developed to maximize depletion of ribosomal RNA from total RNA samples, which is useful to improve the quality of RNA preparations used for applications such as massively parallel sequencing. The RNA depletion method is based on using long affinity-labeled RNA molecules that are complementary to all or part of the target ribosomal RNAs, as subtractive hybridization probes.
Abstract: Engineered Cry1Da amino acid sequences are provided that exhibit improved Lepidopteran insecticidal activity and an enhanced Lepidopteran spectrum compared to the naturally occurring Cry1Da protein toxin. Polynucleotide sequences intended for use in expression of the improved proteins in plants are also provided. Particular embodiments provide compositions containing insect inhibitory amounts of the engineered proteins, as well as recombinant plants, plant parts, and seeds containing polynucleotide constructs encoding one or more of the improved engineered proteins.
Type:
Grant
Filed:
September 22, 2020
Date of Patent:
July 26, 2022
Assignee:
Monsanto Technology LLC
Inventors:
James A. Baum, Thomas Cerruti, Stanislaw Flasinski, Xiaoran Fu, Arlene R. Howe, Sara Ann Salvador
Abstract: A method of treating cardiac hypertrophy and/or heart failure in a subject includes administering to the subject a therapeutically effective amount of a REV-ERB? agonist.
Type:
Grant
Filed:
February 9, 2018
Date of Patent:
July 19, 2022
Assignee:
CASE WESTERN RESERVE UNIVERSITY
Inventors:
Lilei Zhang, Mukesh K. Jain, Thomas Burris
Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize human mesothelin582-598 (IP-NGYLVLDLSMQEALS) (SEQ ID NO: 1) are disclosed. Anti-mesothelin binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are disclosed. Methods of reducing mesothelin shed from cell membranes, methods of reducing the activity of TNF? converting enzyme, methods of detecting the presence of cancer, and methods of treating or preventing cancer are also disclosed.
Type:
Grant
Filed:
May 17, 2018
Date of Patent:
July 19, 2022
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Ira H. Pastan, Masanori Onda, Tapan Bera, Mitchell Ho
Abstract: The present invention relates to a substrate for transglutaminase comprising a peptide having from 3 to 15 amino acids and comprising the amino acid sequence X?4X?3X?2X?1QX+1X+2X+3X+4, bound to a first molecule.
Abstract: Described herein are methods and compositions related to the modulation of progranulin expression or activity in the brain for the treatment of neurodegenerative diseases.
Type:
Grant
Filed:
August 25, 2021
Date of Patent:
June 14, 2022
Assignees:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE CHILDREN'S MEDICAL CENTER CORPORATION
Inventors:
Peter Jungsoo Park, Jin Kuk Kim, Timothy Yu, Yu-Han Huang
Abstract: A composition comprises an anti-nucleolin agent conjugated to nanoparticles. The nanoparticles are non-magnetic, not iron oxide and not polyacrylamide. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
August 18, 2016
Date of Patent:
May 31, 2022
Assignee:
University of Louisville Research Foundation, Inc
Inventors:
Paula J. Bates, Mohammad Tariq Malik, Kyung A. Kang
Abstract: The invention concerns a method of in vitro or ex vivo evaluation of the risk of complications in a patient who has sustained an insult or an infection generating a systemic inflammatory response syndrome, the method being characterized in that it comprises the step of detecting, in a biological sample obtained from said patient, at least one transcript of the IL7R gene, as well as measuring, in vitro or ex vivo, the quantity of at least one transcript of the IL7R gene, in a biological sample from a patient who has sustained an insult or an infection generating a systemic inflammatory response syndrome, in order to evaluate the risk of complications, and in particular of mortality, in said patient. The invention also concerns kits for measuring, in vitro or ex vivo, the quantity of at least one transcript of the IL7R gene in a biological sample.
Type:
Grant
Filed:
December 1, 2016
Date of Patent:
May 24, 2022
Assignees:
BIOMERIEUX, HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BENARD LYON 1
Inventors:
Elisabeth Cerrato, Benjamin Delwarde, Guillaume Monneret, Estelle Peronnet, Julien Textoris, Fabienne Venet
Abstract: There is provided a fusion construct of formula (I): X-A-linker-B-Z (I) wherein: (1) A and B are identical or different and are independently: (a) a polypeptide comprising a SACOL0029 polypeptide as set forth in any one of the sequences depicted in FIG. 24 (SEQ ID NOs: 5 and 121 to 131), a SACOL0264 polypeptide (SEQ ID NO: 185), a SACOL0442 polypeptide as set forth in any one of the sequences depicted in FIG. 22D (SEQ ID NOs: 29 and 82 to 92), a SACOL0718 polypeptide (SEQ ID NO: 186), a SACOL0720 polypeptide as set forth in any one of the sequences depicted in FIGS. 23I-J (SEQ ID NOs: 11 and 109 to 120), a SACOL1353 polypeptide (SEQ ID NO: 187), a SACOL1416 polypeptide (SEQ ID NO: 188), a SACOL1611 polypeptide (SEQ ID NO: 189), a SACOL1867 polypeptide as set forth in any one of the sequences depicted in FIG.
Type:
Grant
Filed:
October 20, 2017
Date of Patent:
May 10, 2022
Assignee:
SOCPRA—SCIENCES ET GENIE, s.e.c.
Inventors:
François Malouin, Céline Ster, Julie Côté-Gravel, Éric Brouillette
Abstract: The present invention relates to a nucleic acid molecule encoding a fusion protein, wherein the nucleic acid molecule comprises: (a) a first nucleic acid sequence encoding a first biosensor, wherein said first biosensor is a first molecule capable of interacting with a second molecule; (b) a second nucleic acid sequence encoding an effector-activating module, wherein the effector-activating module comprises a nucleic acid sequence encoding a first part of a protease, wherein said first part of the protease is capable of interacting with a second part of said protease to form an active form of said protease; (c) a third nucleic acid sequence encoding a third biosensor comprising a protease cleavage site, wherein the protease cleavage site is sterically occluded in the absence of a stimulus for said third biosensor and wherein the protease cleavage site becomes accessible in the presence of said stimulus.
Type:
Grant
Filed:
February 23, 2017
Date of Patent:
May 10, 2022
Assignee:
Korea University Research and Business Foundation
Abstract: In some aspects, the present disclosure provides methods for enriching amplicons, or amplification products, comprising a concatemer of at least two or more copies of a target polynucleotide. In some embodiments, a method comprises sequencing the amplicons comprising at least two or more copies of a target polynucleotide. In some embodiments, the target polynucleotides comprise sequences resulting from chromosome rearrangement, including but not limited to point mutations, single nucleotide polymorphisms, insertions, deletions, and translocations including fusion genes. In some aspects, the present disclosure provides compositions and reaction mixtures useful in the described methods.
Abstract: The present invention aims to provide a nucleic acid compound that hardly forms non-Watson-Crick base pairs, and an oligonucleotide containing the nucleic acid compound and showing reduced non-specific binding with nucleic acids other than the target nucleic acid. The nucleic acid compound according to the present invention is characterized in that the 2-position carbonyl group of the pyrimidine base is functionally converted (X1 and X2 are each independently S or Se), and that the 2?-position and the 4?-position are bridged in a particular structure. The oligonucleotide according to the present invention is characterized in that at least one of thymidine and uridine is the nucleic acid compound.
Abstract: Methods and compositions for increasing the production of recombinant proteins by introducing ICP0 to cells capable of producing a recombinant protein are encompassed. In one method, the recombinant protein is a protein that is required for the replication of a replication defective virus, wherein the recombinant protein is provided to the replication defective virus in trans.
Abstract: Aspects of the invention relate to methods for treating cancer by administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule that is directed against a gene encoding mouse double minute 1 homolog (MDM1), mouse double minute 2 homolog (MDM2), mouse double minute 3 homolog (MDM3), mouse double minute 4 homolog (MDM4) or V-myc myelocytomatosis viral related oncogene (MYCN) for treating cancer. Further aspects of the invention relate to nucleic acid molecules and compositions comprising nucleic acid molecules.
Type:
Grant
Filed:
April 28, 2015
Date of Patent:
March 22, 2022
Assignee:
Phio Pharmaceuticals Corp.
Inventors:
Michael Byrne, Karen G. Bulock, James Cardia